148 related articles for article (PubMed ID: 37781378)
1. Sarcoidosis-like reaction induced by immune checkpoint inhibitor in a patient with hepatocellular carcinoma: a case report.
Torres-Zurita A; Vázquez-Montero L; Gallego-López L; Mediano-Rambla MD; de la Cruz-Merino L
Front Immunol; 2023; 14():1150128. PubMed ID: 37781378
[TBL] [Abstract][Full Text] [Related]
2. Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy: Increased rate and mimicker of metastasis.
Chorti E; Kanaki T; Zimmer L; Hadaschik E; Ugurel S; Gratsias E; Roesch A; Bonella F; Wessendorf TE; Wälscher J; Theegarten D; Schadendorf D; Livingstone E
Eur J Cancer; 2020 May; 131():18-26. PubMed ID: 32248071
[TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint inhibitor-associated sarcoidosis: A usually benign disease that does not require immunotherapy discontinuation.
Chanson N; Ramos-Casals M; Pundole X; Suijkerbuijk K; José de Barros E Silva M; Lidar M; Benesova K; Leipe J; Acar-Denizli N; Pradère P; Michot JM; Voisin AL; Suárez-Almazor ME; Radstake TRD; Fernandes Moça Trevisani V; Schulze-Koops H; Melin A; Robert C; Mariette X; Baughman RP; Lambotte O; ; ; ; ; ;
Eur J Cancer; 2021 Nov; 158():208-216. PubMed ID: 34452793
[TBL] [Abstract][Full Text] [Related]
4. Hilar/mediastinal and cutaneous drug-induced sarcoidosis-like reaction associated with immune checkpoint inhibitors in metastatic colorectal cancer: a case report.
Sagawa T; Sato Y; Nagashima H; Takada K; Takahashi M; Hirakawa M; Hamaguchi K; Tamura F; Fujikawa K; Okamoto K; Kawano Y; Sogabe M; Miyamoto H; Takayama T
Front Immunol; 2023; 14():1203621. PubMed ID: 37492584
[TBL] [Abstract][Full Text] [Related]
5. Rare immune-related adverse events in a patient with metastatic melanoma: a case report highlighting sarcoidosis-like reactions triggered by immune-checkpoint inhibitors.
Cao Y; Afzal MZ; Gutmann EJ; Shirai K
Melanoma Res; 2024 Feb; 34(1):70-75. PubMed ID: 37830935
[TBL] [Abstract][Full Text] [Related]
6. Correlation Between Immune-Related Adverse Events and Prognosis in Hepatocellular Carcinoma Patients Treated With Immune Checkpoint Inhibitors.
Xu S; Lai R; Zhao Q; Zhao P; Zhao R; Guo Z
Front Immunol; 2021; 12():794099. PubMed ID: 34950153
[TBL] [Abstract][Full Text] [Related]
7. Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors.
Wong JSL; Kwok GGW; Tang V; Li BCW; Leung R; Chiu J; Ma KW; She WH; Tsang J; Lo CM; Cheung TT; Yau T
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33563773
[TBL] [Abstract][Full Text] [Related]
8. Sarcoidosis-like reactions in cancer patients treated with immune checkpoint inhibitors: experience in a Spanish hospital.
Torres-Jiménez J; Esteban-Villarrubia J; García-Abellás P; Cortés-Salgado A; Soria-Rivas A; Gajate-Borau P; Olmedo-García ME; Corral-de la Fuente E; Lage-Alfranca Y; Gómez-Rueda A; Benito-Berlinches A; Gorospe-Sarasua L; Garrido-López P
Clin Transl Oncol; 2021 Jul; 23(7):1474-1480. PubMed ID: 33433837
[TBL] [Abstract][Full Text] [Related]
9. Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy.
Tan I; Malinzak M; Salama AKS
J Immunother Cancer; 2018 Jul; 6(1):77. PubMed ID: 30064495
[TBL] [Abstract][Full Text] [Related]
10. Ipilimumab and nivolumab in advanced hepatocellular carcinoma after failure of prior immune checkpoint inhibitor-based combination therapies: a multicenter retrospective study.
Roessler D; Öcal O; Philipp AB; Markwardt D; Munker S; Mayerle J; Jochheim LS; Hammer K; Lange CM; Geier A; Seidensticker M; Reiter FP; De Toni EN; Ben Khaled N
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3065-3073. PubMed ID: 35864269
[TBL] [Abstract][Full Text] [Related]
11. Renal Sarcoidosis-like Reaction Induced by PD-1 Inhibitor Treatment in Non-Small Cell Lung Cancer: A Case Report and Literature Review.
Park SD; Kim MS; Han MH; Kim YJ; Jung HY; Choi JY; Cho JH; Park SH; Kim CD; Kim YL; Lim JH
Medicina (Kaunas); 2023 May; 59(5):. PubMed ID: 37241223
[TBL] [Abstract][Full Text] [Related]
12. Immune checkpoint blocker-related sarcoid-like granulomatous inflammation: a rare adverse event detected in lymph node aspiration cytology of patients treated for advanced malignant melanoma.
Rodriguez EF; Lipson E; Suresh K; Cappelli LC; Monaco SE; Maleki Z
Hum Pathol; 2019 Sep; 91():69-76. PubMed ID: 31279873
[TBL] [Abstract][Full Text] [Related]
13. Myocarditis in a patient treated with Nivolumab and PROSTVAC: a case report.
Monge C; Maeng H; Brofferio A; Apolo AB; Sathya B; Arai AE; Gulley JL; Bilusic M
J Immunother Cancer; 2018 Dec; 6(1):150. PubMed ID: 30563577
[TBL] [Abstract][Full Text] [Related]
14. Myocarditis as an immune-related adverse event following treatment with ipilimumab and nivolumab combination therapy for metastatic renal cell carcinoma: a case report.
Miyauchi Y; Naito H; Tsunemori H; Tani R; Hasui Y; Miyake Y; Minamino T; Ishikawa R; Kushida Y; Haba R; Sugimoto M
J Med Case Rep; 2021 Oct; 15(1):508. PubMed ID: 34649593
[TBL] [Abstract][Full Text] [Related]
15. Immune checkpoint inhibitors associated granulomatous small vessel vasculitis accompanied with tubulointerstitial nephritis: a case report.
Tominaga K; Takeuchi K; Takakuma S; Sakamoto E; Hatanaka S; Kajimoto Y; Toda E; Terasaki Y; Kunugi S; Terasaki M; Shimizu A
BMC Nephrol; 2023 Mar; 24(1):48. PubMed ID: 36894873
[TBL] [Abstract][Full Text] [Related]
16. Erythema Nodosum as the Initial Presentation of Nivolumab-Induced Sarcoidosis-Like Reaction.
Laroche A; Alarcon Chinchilla E; Bourgeault E; Doré MA
J Cutan Med Surg; 2018; 22(6):627-629. PubMed ID: 29772919
[TBL] [Abstract][Full Text] [Related]
17. Sintilimab-Induced Autoimmune Diabetes in a Patient With the Anti-tumor Effect of Partial Regression.
Wen L; Zou X; Chen Y; Bai X; Liang T
Front Immunol; 2020; 11():2076. PubMed ID: 32973816
[TBL] [Abstract][Full Text] [Related]
18. A case of checkpoint inhibitor-induced celiac disease.
Alsaadi D; Shah NJ; Charabaty A; Atkins MB
J Immunother Cancer; 2019 Aug; 7(1):203. PubMed ID: 31383006
[TBL] [Abstract][Full Text] [Related]
19. Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand?
Carloni R; Rizzo A; Ricci AD; Frega G; Federico AD; Palloni A; Marco MD; Gadaleta-Caldarola G; Brandi G
Future Oncol; 2022 Mar; 18(8):1023-1034. PubMed ID: 35109664
[TBL] [Abstract][Full Text] [Related]
20. Sarcoidosis-like syndrome and lymphadenopathy due to checkpoint inhibitors.
Firwana B; Ravilla R; Raval M; Hutchins L; Mahmoud F
J Oncol Pharm Pract; 2017 Dec; 23(8):620-624. PubMed ID: 27590328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
